Search

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors

AI-Driven Model Validated to Predict Risk of CKD Progression

Boehringer Ingelheim and Carelon Research conducted the first large-scale U.S. validation of a new AI-driven tool to predict the risk of CKD progression.

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center

Jardiance® (empagliflozin) analysis reinforces established safety profile

Emmanuelle leads a team of scientists

Want to work for a company that allows you to grow your career? Emmanuelle talks about her job journey at Boehringer Ingelheim.

Candice is moving to Germany

Are you considering a career at Boehringer Ingelheim? Find out why Candice loves working here. For more talent insights, visit our Careers Page.

Leticia develops product medical strategies

Leticia develops product medical strategies at Boehringer Ingelheim. For more talent insights, visit our Careers Page.

Update on sNDA for fibrosing ILD in children and adolescents

Press release providing an update on FDA review of sNDA in children and adolescents with fibrosing interstitial lung disease (ILD)

New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease

Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway

US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction

Phase III EMPA-KIDNEY trial will stop early

The EMPA-KIDNEY trial, evaluating the effect of Jardiance (empagliflozin) tablets in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trial’s Independent Data Monitoring Committee.

Boehringer Ingelheim Announces Jean-Michel Boers as U.S. Country Managing Director, President & CEO Effective August 1, 2020; Dr. Wolfgang Baiker to Retire

BI & Gubra Join Forces to Identify Peptides | Boehringer Ingelheim US

BI & Gubra announce research & licensing agreement focused on the identification & validation of targets & peptide compounds for the treatment of obesity.

Submit Your Partnering Opportunity

Boehringer Ingelheim US Veterinary Scholars Program Profiles | Boehringer Ingelheim US

Click here to find out more how the Boehringer Ingelheim veterinary scholars program has helped 3,500 people over 30 years. Read five of their stories here.

Promising Phase II Results in Chronic Kidney Disease

Boehringer Ingelheim announced promising Phase II data for people with chronic kidney disease

Ridgefield, CT | BI Facilities

BI was established in Connecticut in 1971 and broke ground on September 1st, 1989 in Ridgefield. This site is home to the U.S. HQ of Boehringer Ingelheim

U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes

Oncology & Cancer Immunology

Jardiance shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status

Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease

Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19

HBA Rising Star & Luminary Awards | Boehringer Ingelheim US

Read more on the HBA, is a global nonprofit organization recognizing outstanding individuals and companies who impact and influence women in healthcare.

Translating Human Pharma Science into Animal Health Innovation

Megan Grether shares her perspectives on the importance of translating human pharma science to accelerate innovation in animal health

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers